In this episode, recorded live at BSR25, Professor Robert J Moots joins Professor Ernest Choy to discuss their article reporting on a randomized, controlled, head-to-head clinical trial comparing the two most frequently used biologics in active refractory Behçet’s. Listen now to hear the findings and what this means for future clinical practice! Further reading: You can read this article [https://doi.org/10.1093/rheumatology/keae585] in Rheumatology. Thanks for listening to T...
All content for Talking Rheumatology Research is the property of British Society for Rheumatology and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
In this episode, recorded live at BSR25, Professor Robert J Moots joins Professor Ernest Choy to discuss their article reporting on a randomized, controlled, head-to-head clinical trial comparing the two most frequently used biologics in active refractory Behçet’s. Listen now to hear the findings and what this means for future clinical practice! Further reading: You can read this article [https://doi.org/10.1093/rheumatology/keae585] in Rheumatology. Thanks for listening to T...
Ep 49. Improving time to diagnosis in axial spondyloarthritis
Talking Rheumatology Research
10 minutes
6 months ago
Ep 49. Improving time to diagnosis in axial spondyloarthritis
How can we improve time from symptom onset to axSpA diagnosis? In this episode, Dr Fabian Proft talks to Dr Antoni Chan about his fantastic work to reduce time to diagnosis in axial spondyloarthritis (axSpA) using an integrated referral and education system. They discuss the importance of a multi-pronged approach to education, as well as how clinicians might start improving time to axSpA diagnosis in their own settings. Further reading: Read Antoni's full article in Rheumatology A...
Talking Rheumatology Research
In this episode, recorded live at BSR25, Professor Robert J Moots joins Professor Ernest Choy to discuss their article reporting on a randomized, controlled, head-to-head clinical trial comparing the two most frequently used biologics in active refractory Behçet’s. Listen now to hear the findings and what this means for future clinical practice! Further reading: You can read this article [https://doi.org/10.1093/rheumatology/keae585] in Rheumatology. Thanks for listening to T...
